2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
- PMID: 30092624
- PMCID: PMC6166104
- DOI: 10.3350/cmh.2018.1004
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
Keywords: Chronic hepatitis C; Direct acting antivirals; Guidelines; Treatment.
Conflict of interest statement
Potential conflicts of interests are as follows:
Jong Eun Yeon: Received grants from Pharmaking, Bayer, BMS, Dong-A, Green Cross lab cell.
In Hee Kim: Received honoraria from MSD, Abbvie, Yuhan. Received grants from BMS, Dong-A.
Geum-Youn Gwak: Received honoraria from BMS, Samjin, Dong-A. Received grants from Gilead, BMS, KOWA, SillaJen, Biocompatibles, GSK, Altimmune, Abbvie.
Jung Il Lee: Received honoraria from BMS, Gilead. Received grants from MSD, BMS, Gilead, Bayer, KOWA, Eisai, Novotech, EPS, Ildong, Medigen Biotechnology.
Kyung-Ah Kim: Received grants from MSD, BMS, Gilead.
Ji Hoon Kim: Received honoraria from Gilead, BMS, MSD, Abbvie, Chongkundang, Yuhan, Dong-A, Menarini, Daewoong, Teva. Consulted for Gilead, Abbvie, Chongkundang, Dong-A. Received grants from Gilead, BMS, MSD, Abbvie, Chongkundang, Yuhan, Dong-A, Daewoong, KOWA.
Kang Mo Kim: Received honoraria from Chongkundang, Dong-A, Abbvie, Bayer. Consulted for Bayer, MSD, Chongkundang, GSK. Received grants from Bayer, Dong-A, Yuhan, JW Creagene, MSD.
Jeong Won Jang: Received honoraria from Celltrion, MSD, Abbvie, BMS, Bayer. Received grants from GSK, Altimmune, Sillagen, Spring Bank, Yuhan, Chongkundang, Dong-A.
Do Young Kim: Received honoraria from Abbvie, BMS, Gilead, MSD, Bayer, Eisai, Sirtex, BTG, Yuhan. Consulted for Bayer, SIRTEX, Ono. Received grants from Gilead, Bayer.
Ki Tae Yoon: Received grants from Abbvie, Bayer, BMS, Gilead.
Similar articles
-
A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.Eur J Gastroenterol Hepatol. 2019 Mar;31(3):382-388. doi: 10.1097/MEG.0000000000001299. Eur J Gastroenterol Hepatol. 2019. PMID: 30383554
-
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.Lancet Gastroenterol Hepatol. 2016 Oct;1(2):97-104. doi: 10.1016/S2468-1253(16)30015-2. Epub 2016 Jul 25. Lancet Gastroenterol Hepatol. 2016. PMID: 27917405 Free PMC article. Clinical Trial.
-
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?J Coll Physicians Surg Pak. 2018 May;28(5):414. doi: 10.29271/jcpsp.2018.05.414. J Coll Physicians Surg Pak. 2018. PMID: 29690979 No abstract available.
-
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].Orv Hetil. 2015 May 24;156(21):841-8. doi: 10.1556/650.2015.30177. Orv Hetil. 2015. PMID: 26038991 Review. Hungarian.
-
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Liver Int. 2016 Jan;36 Suppl 1:47-57. doi: 10.1111/liv.13027. Liver Int. 2016. PMID: 26725897 Review.
Cited by
-
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.Gut Liver. 2021 May 15;15(3):440-450. doi: 10.5009/gnl19393. Gut Liver. 2021. PMID: 32839365 Free PMC article.
-
Development and Evaluation of an Antiviral Agent Medication Adherence Education Program for Patients with Chronic Hepatitis C.Int J Environ Res Public Health. 2020 Sep 7;17(18):6518. doi: 10.3390/ijerph17186518. Int J Environ Res Public Health. 2020. PMID: 32906842 Free PMC article.
-
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.Pharmacol Res Perspect. 2021 Aug;9(4):e00811. doi: 10.1002/prp2.811. Pharmacol Res Perspect. 2021. PMID: 34152088 Free PMC article.
-
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1. Clin Mol Hepatol. 2022. PMID: 36263666 Free PMC article.
-
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?Clin Mol Hepatol. 2018 Sep;24(3):294-296. doi: 10.3350/cmh.2018.1009. Epub 2018 Sep 11. Clin Mol Hepatol. 2018. PMID: 30200750 Free PMC article. No abstract available.
References
-
- Sciences G Sovaldi(R) (sofosbuvir), prescribing information. Gilead web site, < http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi...>. Accessed Sep 2017.
-
- Squibb B-M. Daklinza(R) (daclatasvir), prescribing information. Bristol-Myers Squibb web site, < http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi...>. Accessed Accessed Sep 2017.
-
- AbbVie Viekira(R) (dasabuvir, ombitasvir, paritaprevir, and ritonavir), prescribing information. AbbVie web site, < http://www.rxabbvie.com/pdf/viekirapak_pi.pdf>. Accessed Accessed Sep 2017.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources